Axcan Pharma Canasa
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Mesalamine rectal suppositories are approved Jan. 5. At FDA's request, Axcan has been selling mesalamine suppositories as Fivasa since July 1999 on an emergency basis following a recall of Solvay's 5-ASA suppositories Rowasa. Axcan is planning to launch Canasa in April and expects approval for enema and tablet forms in 200